Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Patient Perspectives on the Impact of Adult Spasticity on Daily Life and its Management with Botulinum Toxin Type A
Neuro-rehabilitation
P8 - Poster Session 8 (8:00 AM-9:00 AM)
15-008
To understand the experiences of patients and their caregivers living with spasticity treated with botulinum neurotoxin type A (BoNT-A).
BoNT-A injections are a first-line treatment option for adults with focal spasticity, however little is known about patients’ perspectives regarding their BoNT-A treatment journey.
This was an online international patient survey to capture the treatment experiences of adults with spasticity (post stroke, traumatic brain injury [TBI] or spinal cord injury [SCI]). Eligible patients had ≥2 previous BoNT-A treatments. 
A total of 210 respondents (including 9 caregivers) met screening criteria and their responses were analyzed. About half (52.9%) of patients were male and the median [range] age was 47.5 [18-81] years. Overall, 42.9% of patients had spasticity due to stroke, 30.0% due to TBI, and 27.1% due to SCI. The median age was 44.0 years for the acquired injury. The median time since onset of spasticity was 3.0 years. Over half of patients reported loss of self-confidence (52.4%) and pain (51.4%) due to spasticity; 45.7% reported depression, 41.0% lack of sleep and 39.1% fatigue. Most patients (96.7%) were undergoing BoNT-A treatment, with 35.7% receiving oral antispastic medications, 29.5% participating in home physiotherapy and 19.5% participating in hospital physiotherapy. Overall, 29.1% of patients waited 2-5 years from the date of injury to the first BoNT-A treatment, and 5.7% waited >6 years. Most patients (71.4%) were retreated with BoNT-A every 3-4 months, 14.3% were retreated every 4-6 months and 5.7% at intervals of >6 months. 
The presence of spasticity profoundly impacted many aspects of patients’ lives.  More than a third of patients were injected >2 years after their acquired injury. Typically, patients received regular treatments, in most cases, with reinjection intervals of 3-4 months.
Authors/Disclosures
Alberto Esquenazi, MD (Department of Physical Medicine and Rehabilitation)
PRESENTER 		Dr. Esquenazi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen and Allergan. Dr. Esquenazi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen and Allergan. The institution of Dr. Esquenazi has received research support from Ipsen, Allergan and Merz.
Jorge Jacinto Jorge Jacinto has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz, Ipsen, Allergan. Jorge Jacinto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merz, Allergan, Ipsen.
Andreas Lysandropoulos (Parexel) Andreas Lysandropoulos has nothing to disclose.